Induced Hyper-Osmosis
Our technology combines inhalable hyper-osmotic dry powder formulations with tailored application methods for its deposition in specific regions of the respiratory tract, aligned with specific clinical indications.
Dry NaCl powder inhaler
BREATHOX® is a CE marked medical device registered in the EU, indicated for muco-obstruction. Designed for efficient dry NaCl particle delivery to the respiratory system, it offers an effective and natural alternative to traditional cough and cold products.
Licensing Platform: OSMOVIR®
Instead of targeting specific viral parts like most antivirals, OSMOVIR® addresses viral replication. Though tested on SARS-CoV-2, this treatment paradigm is anticipated to be effective across all viruses due to its mode of action.
Targeting Broad Patient Groups
The LIITA technology platform supports both anitviral and mucoobstructive claims as indicated with the common cold, corunaviruses, COPD, Bronchitis, asthma, and other diseases.
Products
-
Dry/Wet Salt
-
Nasal/Oral
Indications
-
Antiviral
-
Anti-inflammatory
-
Pediatric
Dual-Use Platform
Introducing a transformative treatment form the worlds most prevalent disease in a 41bn€ market.
Civic
Providing a versatile and safe treatment and protection against future pandemics.
Crisis
Relief
Defence
Enhance military readiness by reducing downtime and misuse of antibiotics.
We aspire...
to make the world a better place – to breathe
Our innovative solutions support chronic respiratory patients and those affected by acute respiratory infections in civilian markets. Additionally, we contribute to combating diseases in crisis relief zones and providing essential support to soldiers, ensuring better respiratory health where it is needed the most.
Latest News
Catch up on the latest news & updates here
05 September 2022 • Press Release
New Scientific Discovery Points Toward a Natural Solution for Mild to Moderate Covid-19 Patients
We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
02 September 2022 • Media Update
LIITA Research to be Presented at ERS Congress 2022
We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
Come join us Monday the 5th of September at 12.45 pm (Room 8L).
2022 • News Article
Stay tuned for more news
TBA
Latest News
Catch up on the latest news & updates here
Latest News
Catch up on the latest news & updates here